Drugs /

recombinant ephb4-hsa fusion protein

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant fusion protein composed of the full-length extracellular domain (soluble) of human receptor tyrosine kinase ephrin type-B receptor 4 (sEphB4) and fused, at its C-terminus, to full-length human serum albumin (HSA), with potential antineoplastic and anti-angiogenic activities. sEphB4-HSA functions as a decoy receptor for the membrane-bound ligand Ephrin-B2 (Efnb2) and interferes with the binding of Efnb2 to its native receptors, including EphB4 and EphA3. This may result in a reduction of angiogenesis and a reduction in cell growth of Efnb2 and/or EphB4 over-expressing tumor cells. In addition, this agent also prevents the angiogenic effects of numerous growth factors due to interactions between Efnb2 and EphB4. Efnb2 and EphB4 are overexpressed in a variety of tumor cell types; the bi-directional signaling of Efnb2-EphB4 plays an important role in angiogenesis and tumor cell migration, invasion, and proliferation. Albumin reduces this agent's degradation, improves circulation time and may thus improve efficacy.

Clinical Trials

View Clinical Trials for recombinant ephb4-hsa fusion protein

Recombinant ephb4-hsa fusion protein has been investigated in 11 clinical trials, of which 10 are open and 1 is closed. Of the trials investigating recombinant ephb4-hsa fusion protein, 5 are phase 1 (5 open) and 6 are phase 2 (5 open).

Complex karyotype, KRAS Mutation, and Loss of Y are the most frequent biomarker inclusion criteria for recombinant ephb4-hsa fusion protein clinical trials.

Bladder carcinoma, head and neck squamous cell carcinoma, and non-small cell lung carcinoma are the most common diseases being investigated in recombinant ephb4-hsa fusion protein clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Recombinant Ephb4-Hsa Fusion Protein
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Recombinant Ephb4-Hsa Fusion Protein
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating recombinant ephb4-hsa fusion protein and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
sephb4-hsa
Drug Target(s) [2]:
EFNB2
NCIT ID [1]:
C102569

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.